361 related articles for article (PubMed ID: 28027945)
1. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
2. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
Robinson CL; Harrison BT; Ligon AH; Dong F; Maffeis V; Matulonis U; Nucci MR; Kolin DL
Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
[TBL] [Abstract][Full Text] [Related]
3. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
[TBL] [Abstract][Full Text] [Related]
4. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
5. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
[TBL] [Abstract][Full Text] [Related]
6. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
Xia D; Kuo F; Hughes M; Lindeman N; Manning D; Files J; Strauss S; Kirkner G; Mohammed-Abreu A; Winer E; Tolaney SM; Lin NU; Dillon DA
Am J Clin Pathol; 2024 May; 161(5):436-442. PubMed ID: 38104247
[TBL] [Abstract][Full Text] [Related]
7. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
10. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
Ferguson DC; Momeni Boroujeni A; Zheng T; Mohanty AS; Ho AL; Arcila ME; Ross DS; Dogan S
Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
[TBL] [Abstract][Full Text] [Related]
11. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
12. Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry.
Choi S; Chu J; Kim B; Ha SY; Kim ST; Lee J; Kang WK; Han H; Sohn I; Kim KM
J Mol Diagn; 2019 Jul; 21(4):612-622. PubMed ID: 31022472
[TBL] [Abstract][Full Text] [Related]
13. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
Ni R; Mulligan AM; Have C; O'Malley FP
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
[TBL] [Abstract][Full Text] [Related]
14. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
[TBL] [Abstract][Full Text] [Related]
17. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer.
Ahn S; Hong M; Van Vrancken M; Lyou YJ; Kim ST; Park SH; Kang WK; Park YS; Jung SH; Woo M; Lee J; Kim KM
Mol Diagn Ther; 2016 Aug; 20(4):375-83. PubMed ID: 27179810
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
19. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
[TBL] [Abstract][Full Text] [Related]
20. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
Shah AN; Sunderraj A; Finkelman B; See SH; Davis AA; Gerratana L; Wehbe F; Katam N; Mahalingam D; Gradishar WJ; Behdad A; Blanco L; Cristofanilli M
Oncotarget; 2022; 13():273-280. PubMed ID: 35126865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
